These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20123381)

  • 1. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
    Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis.
    Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203
    [No Abstract]   [Full Text] [Related]  

  • 7. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
    Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
    Marcussen M; Bødker JS; Christensen HS; Johansen P; Nielsen S; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
    PLoS One; 2017; 12(1):e0169286. PubMed ID: 28052121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.
    Avivi I; Avraham S; Koren-Michowitz M; Zuckerman T; Aviv A; Ofran Y; Benyamini N; Nagler A; Rowe JM; Nagler RM
    Bone Marrow Transplant; 2009 May; 43(10):801-6. PubMed ID: 19029961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
    de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
    Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
    Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
    Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C
    Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
    Moreau P; Milpied N; Mahé B; Juge-Morineau N; Rapp MJ; Bataille R; Harousseau JL
    Bone Marrow Transplant; 1999 May; 23(10):1003-6. PubMed ID: 10373065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravital sidestream dark-field (SDF) imaging is used in a rabbit model for continuous noninvasive monitoring and quantification of mucosal capillary regeneration during wound healing in the oral cavity: a pilot study.
    Milstein DM; Lindeboom JA; Ince C
    Arch Oral Biol; 2010 May; 55(5):343-9. PubMed ID: 20378098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.